Medical technology company BD (Becton, Dickinson and Company) announced on Monday that it has launched its first high-throughput, robotics-compatible reagent kit aimed at automating large-scale, single-cell discovery studies.
By integrating Hamilton's robotics with BD's reagent kits, this solution enhances workflow efficiency, minimizes human error and accelerates research in fields like oncology and immunology. The collaboration also standardizes manual processes and speeds up the generation of material for genetic sequencing.
Featuring BD's OMICS-One XT WTA Assay and Hamilton's Microlab NGS STAR platform, the automated solution allows for seamless integration into existing laboratory workflows. Researchers worldwide can now improve consistency and throughput in genomics applications. Traditional manual DNA library construction, previously time-consuming and prone to variability, is now streamlined, reducing costs and turnaround times.
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
RevOpsis Therapeutics receives SBIR grant of over USD1.8m
AtomVie Global Radiopharma partners with Radiopharm Ventures
Lipella granted patent for innovative drug delivery technology
Adocia patents stable hormone combinations for obesity and diabetes
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial